Unknown

Dataset Information

0

Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.


ABSTRACT: BACKGROUND:There is no good prognostic model that could predict the prognosis of bladder cancer (BCa) and the benefit of immunotherapy. METHODS:Through the least absolute shrinkage and selection operator (LASSO) algorithm, we constructed a 13-mRNA immune signature from the TCGA cohort (n = 406). We validated its prognostic value and predictive value for the benefit of immunotherapy with four independent validation cohort (GSE13507 [n = 256], GSE31684 [n = 93], GSE32894 [n = 308], and IMvigor210 cohort [n = 298]). RESULTS:Our results indicating that high-risk group with higher inhibitory immune cell infiltration (regulatory T cells [Tregs] and macrophage, etc), higher expression of immune checkpoints, and more T cell suppressive pathways (transforming growth factor ? [TGF-?], epithelial-mesenchymal transition [EMT], etc) were activated. Besides, the immune signature showed a good predictive value for the benefit of immunotherapy in a cohort of urothelial carcinoma patients treated with PD-L1. CONCLUSIONS:The immune signature constructed is convenient to classify the immunotherapeutic susceptibility of patients with BCa, so as to achieve precision immunotherapy for BCa.

SUBMITTER: Wang Y 

PROVIDER: S-EPMC7571842 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.

Wang Yejinpeng Y   Chen Liang L   Yu Mengxue M   Fang Yayun Y   Qian Kaiyu K   Wang Gang G   Ju Lingao L   Xiao Yu Y   Wang Xinghuan X  

Cancer medicine 20200825 20


<h4>Background</h4>There is no good prognostic model that could predict the prognosis of bladder cancer (BCa) and the benefit of immunotherapy.<h4>Methods</h4>Through the least absolute shrinkage and selection operator (LASSO) algorithm, we constructed a 13-mRNA immune signature from the TCGA cohort (n = 406). We validated its prognostic value and predictive value for the benefit of immunotherapy with four independent validation cohort (GSE13507 [n = 256], GSE31684 [n = 93], GSE32894 [n = 308],  ...[more]

Similar Datasets

| S-EPMC8893690 | biostudies-literature
| S-EPMC8370985 | biostudies-literature
| S-EPMC10795461 | biostudies-literature
| S-EPMC10017825 | biostudies-literature
| S-EPMC10373974 | biostudies-literature
| S-EPMC9701826 | biostudies-literature
| S-EPMC9126043 | biostudies-literature
| S-EPMC6635287 | biostudies-literature
| S-EPMC8635160 | biostudies-literature
| S-EPMC9245204 | biostudies-literature